2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.
Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the emergence of CAR T-cell therapy in hematologic malignancies.
CAR T-cell therapy has demonstrated encouraging activity in adults with relapsed/refractory non-Hodgkin lymphoma and pediatric patients with relapsed/refractory acute lymphoblastic leukemia, says Shaughnessy
Several ongoing studies are evaluating CAR T-cell therapy in multiple myeloma and other types of lymphoma, explains Shaughnessy. Moreover, the encouraging results observed thus far suggest that CAR T-cell therapy will receive regulatory approval in additional indications in the future.
Beyond the hematologic space, CAR T-cell therapy could have utility in solid tumors, Shaughnessy concludes.